Despite their potential, NAMs face several challenges. One major issue is regulatory acceptance; many regulatory bodies still require traditional testing data for safety evaluations. Additionally, NAMs require significant upfront investment in terms of technology and expertise. There is also the challenge of ensuring that these new methodologies provide data that are as reliable and comprehensive as those obtained from traditional methods. Bridging these gaps is crucial for the broader adoption of NAMs in toxicology.
